Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.34 |
| ▸ | SQOR | Q9Y6N5 | 6/20 | 0.32 |
| ▸ | USP7 | Q93009 | 2/20 | 0.32 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17123788 | 0.79 | USP8 (0.40) | USP8RECQLMAP4K1SQORUSP7 | |
| SCHEMBL620504 | 0.78 | USP8 (0.42) | USP8RECQLMAP4K1KDM4E | |
| SCHEMBL13256727 | 0.76 | KMT2A (0.36) | RECQLKDM4EALDH1A1KMT2A | |
| SCHEMBL20106531 | 0.75 | CHEK1 (0.40) | USP8MAP4K1 | |
| SCHEMBL18220678 | 0.71 | KMT2A (0.30) | KMT2A | |
| SCHEMBL14590435 | 0.70 | FFAR1 (0.38) | USP8RECQLSQORKDM4EALDH1A1 | |
| SCHEMBL18185851 | 0.69 | MAPK8 (0.43) | USP8MAP4K1HPGDGAA | |
| SCHEMBL14316177 | 0.69 | USP8 (0.46) | USP8RECQLSQORUSP7HPGDS | |
| SCHEMBL20261935 | 0.68 | RECQL (0.41) | USP8RECQLSQORUSP7KDM4E | |
| SCHEMBL23700104 | 0.68 | USP8 (0.40) | USP8RECQLMAP4K1SQORUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3529250-B1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2023-12-06 | — | — | EP | disclosed |
| CN-109843884-B | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors | H.隆德贝克有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-10633382-B2 | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-04-28 | — | — | US | disclosed |
| US-10633382-B2 | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-04-28 | — | — | US | disclosed |
| US-20190308968-A1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-10-10 | — | — | US | disclosed |
| US-20190308968-A1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-10-10 | — | — | US | disclosed |
| EP-3529250-A1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2019-08-28 | — | — | EP | disclosed |
| CN-109843884-A | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H.隆德贝克有限公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018073251-A1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018073251-A1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308968-A1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | PDE5A, PDE12, PDE3A | USP8 3468/4885RECQL 619/4885MAP4K1 661/4885 |
| US-10633382-B2 | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors | PDE5A, PDE12, PDE3A | USP8 3468/4885RECQL 619/4885MAP4K1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.